Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc is a clinical stage pharmaceutical company. It is dedicated to the research and development of light activated Photo Dynamic Compounds, their associated drug formulations and technology platforms intended to safely and effectively; treat various cancers, bacteria and viruses. The Cool Laser Technology division designs, develops, manufactures and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, primarily in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (TSXV:TLT)

Fundamentals Snapshot (TSXV:TLT)

Bullboard Posts (TSXV:TLT)

RE:RE:Pre-FDA approval deals

Gleevec was a blockbuster cancer drug for Novartis two decades ago.  They need something new. A new class of metal-based drugs like...
N0taP00p - 41 minutes ago

RE:Pre-FDA approval deals

Prometheus was clinical late stage when Merck bought it for nearly 11B.  Bowel disease. 
N0taP00p - 51 minutes ago

RE:Pre-FDA approval deals

This is for the Toxic Avenger drug... 2018: Novartis will buy the Indiana-based biotech Endocyte and its experimental...
DeathXray33 - 1 hour ago

Pre-FDA approval deals

Anyone have example(s) of such?
jmm1228 - 2 hours ago

RE:RE:RE:RE:RE:RE:How many big pharmas and what are they buying

Actually StevenBirch a rough estimate of fair value can be calculated by the average number of new patients per year with say 2 to 3...
99942Apophis - 4 hours ago

RE:RE:RE:RE:RE:How many big pharmas and what are they buying

Interesting but it would be really hard to assess fair value this early in the GBM and NSCLC process. If we are right and "the...
StevenBirch - 4 hours ago